BCR-ABL1 mutation ≠ ponatinib resistance

被引：4
|
作者：
Saglio, Giuseppe [1 ]
Fava, Carmen [1 ]
机构：
[1] Univ Turin, I-10124 Turin, Italy
来源：
BLOOD | 2016年 / 127卷 / 06期
关键词：
CHRONIC MYELOID-LEUKEMIA; CHROMOSOME-POSITIVE LEUKEMIAS; INHIBITOR; AP24534; POTENT;
D O I：
10.1182/blood-2015-12-685149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：666 / +
页数：2
相关论文
共 50 条
  • [1] Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia
    Gibbons, Don L.
    Pricl, Sabrina
    Posocco, Paola
    Laurini, Erik
    Fermeglia, Maurizio
    Talpaz, Moshe
    Cortes, Jorge E.
    Donato, Nicholas J.
    Quintas-Cardama, Alfonso
    BLOOD, 2013, 122 (21)
  • [2] Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
    Singh Anand, Anand Prakash
    Umbarkar Prachi, Prachi
    Tousif, Sultan
    Lal, Hind
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 214 - 221
  • [3] GilteritinibDrug resistance secondary to acquisition of BCR-ABL1 mutation: case report
    Reactions Weekly, 2020, 1819 (1) : 131 - 131
  • [4] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
    Parker, Wendy T.
    Yeung, David T. O.
    Yeoman, Alexandra L.
    Altamura, Haley K.
    Jamison, Bronte A.
    Field, Chani R.
    Hodgson, J. Graeme
    Lustgarten, Stephanie
    Rivera, Victor M.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2016, 127 (15) : 1870 - 1880
  • [5] Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
    Deininger, Michael W.
    Hodgson, J. Graeme
    Shah, Neil P.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Mueller, Martin C.
    Li, Jin
    Parker, Wendy T.
    Lustgarten, Stephanie
    Clackson, Tim
    Haluska, Frank G.
    Guilhot, Francois
    Kantarjian, Hagop M.
    Soverini, Simona
    Hochhaus, Andreas
    Hughes, Timothy P.
    Rivera, Victor M.
    Branford, Susan
    BLOOD, 2016, 127 (06) : 703 - 712
  • [6] ImatinibDrug resistance due to 35 nucleotides BCR-ABL1 insertion mutation: case report
    Reactions Weekly, 2015, 1555 (1) : 104 - 104
  • [7] MODELLING PONATINIB RESISTANCE IN BCR-ABL1+CELL LINES: IMPLICATIONS FOR PONATINIB THERAPY
    Lu, L.
    Saunders, V.
    Kok, C.
    Leclercq, T.
    Hughes, T.
    White, D.
    HAEMATOLOGICA, 2016, 101 : 182 - 183
  • [8] Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
    Qiang, W.
    Antelope, O.
    Zabriskie, M. S.
    Pomicter, A. D.
    Vellore, N. A.
    Szankasi, P.
    Rea, D.
    Cayuela, J. M.
    Kelley, T. W.
    Deininger, M. W.
    O'Hare, T.
    LEUKEMIA, 2017, 31 (12) : 2844 - 2847
  • [9] Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
    W Qiang
    O Antelope
    M S Zabriskie
    A D Pomicter
    N A Vellore
    P Szankasi
    D Rea
    J M Cayuela
    T W Kelley
    M W Deininger
    T O’Hare
    Leukemia, 2017, 31 : 2844 - 2847
  • [10] BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
    Byrgazov, K.
    Lucini, C.
    Printz, D.
    Koenig, M.
    Valent, P.
    Hantschel, O.
    Lion, T.
    HAEMATOLOGICA, 2017, 102 : 233 - 233
12345